Additionally, the therapeutic targeting of Neu-1 with oseltamivir and aspirin with gemcitabine (GEM) treatment significantly disrupts critical signaling mechanisms, tumor progression, and metastasis in a preclinical mouse model of human pancreatic cancer [114]. Here, NEU1 is linked to pancreatic neoplasm.